Document Type : Original Article(s)
Authors
1 Metabolic Disorders Research Center, Biomedical Research Institute, Golestan University of Medical Sciences, Gorgan, Iran
2 Department of Biochemistry and Biophysics, Faculty of Medicine, Golestan University of Medical Sciences, Gorgan, Iran
Abstract
Background: Esophageal cancer is one of the most devastating cancers of the gastrointestinal tract. We will compare the expression levels of fibrillin-1 (FBN1) and fibrillin-2 (FBN2), a family of extracellular matrix glycoproteins, in esophageal cancer with normal adjacent tumor tissue.
Methods: In this cross-sectional study, 22 esophageal squamous cell carcinoma (ESCC) tumor samples and their matched adjacent normal tissues were collected from hospitals in Gorgan City (Golestan, Iran) between 2020 and 2022. After RNA extraction and cDNA synthesis, we measured the semi-quantitative gene expression level using real-time polymerase chain reaction (PCR). Data from this study were analyzed using SPSS software (version 18), and results were considered statistically significant when the P was <0.05. The primary statistical analyses used in this study were the Paired Samples t test and the Wilcoxon signed-rank test.
Results: The expression of the FBN1 gene decreased in tumor tissue compared to normal tissue (the FBN1 gene fold change=0.5472±0.149, P=0.007), and the FBN2 gene expression increased in tumor tissue compared to normal tissue (the FBN2 gene fold change=7.341±1.299, P<0.0001). We found no significant association between FBN1 and FBN2 gene expression and the clinicopathological features.
Conclusion: The change in FBN1 and FBN2 expression levels in the tumor tissue compared to normal tissue in ESCC suggests that FBN1 and FBN2 genes can be considered therapeutic targets for ESCC.
Highlights
Mahsa Mahdizadeh (Google Scholar)
Seyyed Mehdi Jafari (Google Scholar)
Keywords
- Song G, Liu K, Yang X, Mu B, Yang J, He L, et al. SATB1 plays an oncogenic role in esophageal cancer by up-regulation of FN1 and PDGFRB. Oncotarget. 2017;8:17771-84. doi: 10.18632/oncotarget.14849. PubMed PMID: 28147311; PubMed Central PMCID: PMCPMC5392285.
- Xu W, Xu J, Wang Z, Jiang Y. Weighted Gene Correlation Network Analysis Identifies Specific Functional Modules and Genes in Esophageal Cancer. J Oncol. 2021;2021:8223263. doi: 10.1155/2021/8223263. PubMed PMID: 34987580; PubMed Central PMCID: PMCPMC8723838.
- Huang FL, Yu SJ. Esophageal cancer: Risk factors, genetic association, and treatment. Asian J Surg. 2018;41:210-5. doi: 10.1016/j.asjsur.2016.10.005. PubMed PMID: 27986415.
- Nie Y, Yao G, Xu X, Liu Y, Yin K, Lai J, et al. Single-cell mapping of N6-methyladenosine in esophageal squamous cell carcinoma and exploration of the risk model for immune infiltration. Front Endocrinol (Lausanne). 2023;14:1155009. doi: 10.3389/fendo.2023.1155009. PubMed PMID: 37025404; PubMed Central PMCID: PMCPMC10070687.
- Mahdizadehi M, Saghaeian Jazi M, Mir SM, Jafari SM. Role of fibrilins in human cancer: A narrative review. Health Sci Rep. 2023;6:e1434. doi: 10.1002/hsr2.1434. PubMed PMID: 37469709; PubMed Central PMCID: PMCPMC10353528.
- Genovesi ML, Torres B, Goldoni M, Salvo E, Cesario C, Majolo M, et al. Case Report: A Novel Homozygous Missense Variant of FBN3 Supporting It Is a New Candidate Gene Causative of a Bardet-Biedl Syndrome-Like Phenotype. Front Genet. 2022;13:924362. doi: 10.3389/fgene.2022.924362. PubMed PMID: 35910214; PubMed Central PMCID: PMCPMC9334770.
- van Loon K, Yemelyanenko-Lyalenko J, Margadant C, Griffioen AW, Huijbers EJM. Role of fibrillin-2 in the control of TGF-beta activation in tumor angiogenesis and connective tissue disorders. Biochim Biophys Acta Rev Cancer. 2020;1873:188354. doi: 10.1016/j.bbcan.2020.188354. PubMed PMID: 32119940.
- Kumra H, Reinhardt DP. Fibrillins. Methods Cell Biol. 2018;143:223-46. doi: 10.1016/bs.mcb.2017.08.013. PubMed PMID: 29310780.
- Godwin ARF, Singh M, Lockhart-Cairns MP, Alanazi YF, Cain SA, Baldock C. The role of fibrillin and microfibril binding proteins in elastin and elastic fibre assembly. Matrix Biol. 2019;84:17-30. doi: 10.1016/j.matbio.2019.06.006. PubMed PMID: 31226403; PubMed Central PMCID: PMCPMC6943813.
- Thomson J, Singh M, Eckersley A, Cain SA, Sherratt MJ, Baldock C. Fibrillin microfibrils and elastic fibre proteins: Functional interactions and extracellular regulation of growth factors. Semin Cell Dev Biol. 2019;89:109-17. doi: 10.1016/j.semcdb.2018.07.016. PubMed PMID: 30016650; PubMed Central PMCID: PMCPMC6461133.
- Lockhart-Cairns MP, Cain SA, Dajani R, Steer R, Thomson J, Alanazi YF, et al. Latent TGFbeta complexes are transglutaminase cross-linked to fibrillin to facilitate TGFbeta activation. Matrix Biol. 2022;107:24-39. doi: 10.1016/j.matbio.2022.01.005. PubMed PMID: 35122964; PubMed Central PMCID: PMCPMC8932414.
- Del Cid JS, Reed NI, Molnar K, Liu S, Dang B, Jensen SA, et al. A disease-associated mutation in fibrillin-1 differentially regulates integrin-mediated cell adhesion. J Biol Chem. 2019;294:18232-43. doi: 10.1074/jbc.RA119.011109. PubMed PMID: 31640988; PubMed Central PMCID: PMCPMC6885615.
- Wang H, Liu Z, Zhang G. FBN1 promotes DLBCL cell migration by activating the Wnt/beta-catenin signaling pathway and regulating TIMP1. Am J Transl Res. 2020;12:7340-53. PubMed PMID: 33312371; PubMed Central PMCID: PMCPMC7724331.
- Hernandiz A, Zuniga A, Valera F, Domingo D, Ontoria-Oviedo I, Mari JF, et al. Genotype FBN1/phenotype relationship in a cohort of patients with Marfan syndrome. Clin Genet. 2021;99:269-80. doi: 10.1111/cge.13879. PubMed PMID: 33174221.
- Overwater E, Efrat R, Barge-Schaapveld D, Lakeman P, Weiss MM, Maugeri A, et al. Autosomal dominant Marfan syndrome caused by a previously reported recessive FBN1 variant. Mol Genet Genomic Med. 2019;7:e00518. doi: 10.1002/mgg3.518. PubMed PMID: 30485715; PubMed Central PMCID: PMCPMC6393656.
- Wang Z, Liu Y, Lu L, Yang L, Yin S, Wang Y, et al. Fibrillin-1, induced by Aurora-A but inhibited by BRCA2, promotes ovarian cancer metastasis. Oncotarget. 2015;6:6670-83. doi: 10.18632/oncotarget.3118. PubMed PMID: 25749384; PubMed Central PMCID: PMCPMC4466642.
- Luan H, Zhang C, Zhang T, He Y, Su Y, Zhou L. Identification of Key Prognostic Biomarker and Its Correlation with Immune Infiltrates in Pancreatic Ductal Adenocarcinoma. Dis Markers. 2020;2020:8825997. doi: 10.1155/2020/8825997. PubMed PMID: 32934754; PubMed Central PMCID: PMCPMC7479484.
- Yin W, Kim HT, Wang S, Gunawan F, Li R, Buettner C, et al. Fibrillin-2 is a key mediator of smooth muscle extracellular matrix homeostasis during mouse tracheal tubulogenesis. Eur Respir J. 2019;53. doi: 10.1183/13993003.00840-2018. PubMed PMID: 30578393.
- Peeters S, De Kinderen P, Meester JAN, Verstraeten A, Loeys BL. The fibrillinopathies: New insights with focus on the paradigm of opposing phenotypes for both FBN1 and FBN2. Hum Mutat. 2022;43:815-31. doi: 10.1002/humu.24383. PubMed PMID: 35419902; PubMed Central PMCID: PMCPMC9322447.
- Hong Q, Li R, Zhang Y, Gu K. Fibrillin 2 gene knockdown inhibits invasion and migration of lung cancer cells. Cell Mol Biol (Noisy-le-grand). 2020;66:190-6. PubMed PMID: 33287941.
- Summers KM. Genetic models of fibrillinopathies. Genetics. 2024;226. doi: 10.1093/genetics/iyad189. PubMed PMID: 37972149; PubMed Central PMCID: PMCPMC11021029.
- Zhai X, Xue Q, Liu Q, Guo Y, Chen Z. Colon cancer recurrenceassociated genes revealed by WGCNA coexpression network analysis. Mol Med Rep. 2017;16:6499-505. doi: 10.3892/mmr.2017.7412. PubMed PMID: 28901407; PubMed Central PMCID: PMCPMC5865817.
- Lu Z, Lu Z, Lai Y, Zhou H, Li Z, Cai W, et al. A comprehensive analysis of FBN2 in bladder cancer: A risk factor and the tumour microenvironment influencer. IET Syst Biol. 2023;17:162-73. doi: 10.1049/syb2.12067. PubMed PMID: 37337404; PubMed Central PMCID: PMCPMC10439492.
- Yi JM. DNA Methylation Change Profiling of Colorectal Disease: Screening towards Clinical Use. Life (Basel). 2021;11. doi: 10.3390/life11050412. PubMed PMID: 33946400; PubMed Central PMCID: PMCPMC8147151.
- Tseleni-Balafouta S, Gakiopoulou H, Fanourakis G, Voutsinas G, Litsiou H, Sozopoulos E, et al. Fibrillin expression and localization in various types of carcinomas of the thyroid gland. Mod Pathol. 2006;19:695-700. doi: 10.1038/modpathol.3800578. PubMed PMID: 16528372.
)